

PROHIBITION OF SALES TO EEA RETAIL INVESTORS: The Securities are not intended to be offered, sold or otherwise made available to and may not be offered, sold or otherwise made available to any retail investor in the European Economic Area ("**EEA**"). For these purposes, retail investor means a person who is one (or more) of: (i) a retail client as defined in point (11) of Article 4(1) of Directive 2014/65/EU on Markets in Financial Instruments (as may be amended, varied or replaced from time to time) ("**MiFID II**"); (ii) a customer within the meaning of Directive (EU) 2016/97 (the "**Insurance Distribution Directive**"), where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of MiFID II; or (iii) not a qualified investor as defined in the Prospectus Regulation. Consequently no key information document required by Regulation (EU) No 1286/2014 (the "**PRIIPs Regulation**") for offering or selling the Securities or otherwise making them available to retail investors in the EEA has been prepared and therefore offering or selling such Securities or otherwise making them available to any retail investor in the EEA may be unlawful under the PRIIPs Regulation.

PROHIBITION OF SALES TO UK RETAIL INVESTORS: The Securities are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail investor in the United Kingdom ("**UK**"). For these purposes, a retail investor means a person who is one (or more) of: (i) a retail client, as defined in point (8) of Article 2 of Regulation (EU) No 2017/565 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 ("**EUWA**"); (ii) a customer within the meaning of the provisions of the Financial Services and Markets Act 2000, as amended (the "**FSMA**") and any rules or regulations made under the FSMA to implement Directive (EU) 2016/97, where that customer would not qualify as a professional client, as defined in point (8) of Article 2(1) of Regulation (EU) No 600/2014 as it forms part of domestic law by virtue of the EUWA; or (iii) not a qualified investor as defined in Article 2 of Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the EUWA. Consequently no key information document required by Regulation (EU) No 1286/2014 as it forms part of domestic law by virtue of the EUWA (the "**UK PRIIPs Regulation**") for offering or selling the Securities or otherwise making them available to retail investors in the UK has been prepared and therefore offering or selling such Securities or otherwise making them available to any retail investor in the UK may be unlawful under the UK PRIIPs Regulation.



Credit Suisse AG, London Branch

Legal Entity Identifier (LEI): ANGGYXNX0JLX3X63JN86

USD 6,000,000 Trigger Yield Securities linked to a Share Basket, due October 2024 (the "**Notes**" or the "**Securities**")

Series: SPLB2021-1ZQP

ISIN: XS2387777555

Issue Price: 100 per cent. of the Aggregate Nominal Amount

Summary and Securities Note

This document comprises two parts:

- Part One is a summary of the Registration Document and Securities Note (the "**Summary**"); and
- Part Two is a securities note (the "**Securities Note**").

The Summary and Securities Note contain information relating to the above Securities.

Registration Document

The Summary and Securities Note shall be read in conjunction with the registration document dated 11 June 2021 (the "**Original Registration Document**") as supplemented by a supplement dated 20 July 2021, a supplement dated 5 August 2021, a supplement dated 29 October 2021 and a supplement dated 12 November 2021 (the Original Registration Document as so supplemented and as may be further supplemented from time to time, the "**Registration Document**") containing information in respect of Credit Suisse AG (the "**Issuer**").

Prospectus

Together, the Registration Document, the Summary and the Securities Note constitute a "prospectus" (the "**Prospectus**") for the Securities, prepared for the purposes of Article 6(3) of Regulation (EU) 2017/1129, as amended (the "**Prospectus Regulation**"). The Prospectus and all related notices will be published on the website of the Luxembourg Stock Exchange (www.bourse.lu) and the website of the Issuer (<https://derivative.credit-suisse.com>).

This Prospectus is valid for 12 months after its approval and will expire on 17 November 2022, provided that it is completed by any supplement required pursuant to Article 23 of the Prospectus Regulation. The obligation to supplement a prospectus in the event of any significant new factor, material mistake or material inaccuracy relating to the information included in this Prospectus does not apply when a prospectus is no longer valid or if such significant new factor, material mistake or material inaccuracy arises or is noted after the time when trading on a regulated market begins.

Programme

The Prospectus is one of a number of prospectuses under the Structured Products Programme for the issuance of Notes, Certificates and Warrants (the "**Programme**") of the Issuer.

The Securities

The Securities are in the form of Notes and are issued by the Issuer under the Programme. The terms and conditions of the Securities will comprise:

- the General Terms and Conditions of Notes (the "**General Conditions**") as incorporated by reference from the Securities Note dated 9 July 2021 (the "**Original CS Trigger Redeemable and Phoenix Securities Note**") and as supplemented by a supplement dated 3 August 2021 (the "**Supplement dated 3 August 2021 to the Original CS Trigger Redeemable and Phoenix Securities Note**"), and together with the Original CS Trigger Redeemable and Phoenix Securities Note, the "**CS Trigger Redeemable and Phoenix Securities Note**") as part of the Trigger Redeemable and Phoenix Securities Base Prospectus pursuant to the Structured Products Programme for the issuance of Notes, Certificates and Warrants;
- the applicable Product Conditions (the "**Product Conditions**") as incorporated by reference from the CS Trigger Redeemable and Phoenix Securities Note and as amended herein;
- the Asset Terms for Equity-linked Securities (the "**Asset Terms**") as incorporated by reference from the CS Trigger Redeemable and Phoenix Securities Note; and
- the specific terms of the Securities, as completing and amending the General Conditions, the Product Conditions and the Asset Terms, as set forth in "**Specific Terms**" below.

This Summary and Securities Note also incorporates by reference certain other information from the CS Trigger Redeemable and Phoenix Securities Note (see "Documents Incorporated by Reference" below).

Underlying Assets

The return on the Securities is linked to the performance of (a) the ordinary shares of Arrowhead Pharmaceuticals Inc, (b) the ordinary shares of Ultragenyx Pharmaceutical Inc, (c) the ordinary shares of Invitae Corporation and (d) the ordinary shares of CRISPR Therapeutics AG (each, an "**Underlying Asset**", and together, the "**Underlying Assets**").

Risk factors

Depending on the performance of the Underlying Assets, you may lose some or all of your investment in the Securities.

Before purchasing any Securities, you should consider, in particular, the information in the section entitled "Risk Factors" below together with the relevant risk factors relating to the Issuer set out in the Registration Document.

17 November 2021

IMPORTANT NOTICES

Potential for discretionary determinations by the Issuer under the Securities

Under the terms and conditions of the Securities, following the occurrence of certain events outside of its control, the Issuer may determine in its discretion to take one or more of the actions available to it in order to address the impact of such event on the Securities or the Issuer or both. It is possible that any such discretionary determination by the Issuer could have a material adverse impact on the value of and return on the Securities.

No investment advice

Prospective investors should have regard to the factors described under the section headed "Risk Factors" in the Securities Note. The Issuer is acting solely in the capacity of an arm's length contractual counterparty and not as an investor's financial adviser or fiduciary in any transaction. The purchase of Securities involves substantial risks and an investment in Securities is only suitable for investors who (either alone or in conjunction with an appropriate financial adviser) fully evaluate the risks and merits of such an investment in the Securities and who have sufficient resources to be able to bear any losses that may result therefrom.

Therefore, before making an investment decision, prospective investors of Securities should ensure that they understand the nature of the Securities and the extent of their exposure to risks and consider carefully, in the light of their own financial circumstances, financial condition and investment objectives, all the information set forth in the Prospectus and any documents incorporated by reference herein. The Prospectus cannot disclose whether the Securities are a suitable investment in relation to any investor's particular circumstances; therefore investors should consult their own financial, tax, legal or other advisers if they consider it appropriate to do so and carefully review and consider such an investment decision in the light of the information set forth in the Prospectus.

No other person is authorised to give information on the Securities

In connection with the issue and sale of the Securities, no person is authorised by the Issuer to give any information or to make any representation not contained in the Registration Document, the Summary or the Securities Note, and neither the Issuer nor the Dealer accepts responsibility for any information or representation so given that is not contained in the Registration Document, the Summary or the Securities Note.

Not an offer

Except as specified herein, the Prospectus does not constitute an offer to the public of Securities, and may not be used for the purposes of an offer to the public or solicitation by anyone, in any jurisdiction in which such offer or solicitation is not authorised, or to any person to whom it is unlawful to make such offer or solicitation and no action is being taken to permit an offering of the Securities to the public or the distribution of the Prospectus in any jurisdiction where any such action is required.

Restrictions on distribution

The distribution of the Prospectus and the offering of the Securities in certain jurisdictions may be restricted by law. Persons into whose possession the Registration Document, the Summary or the Securities Note, comes are required by the Issuer to inform themselves about, and to observe, such restrictions. For a description of certain restrictions on offers or sales of the Securities and the distribution of the Prospectus and other offering materials relating to the Securities, please refer to the section entitled "Selling Restrictions" of the Original CS Trigger Redeemable and Phoenix Securities Note and as supplemented by the Supplement dated 3 August 2021 to the Original CS Trigger Redeemable and Phoenix Securities Note, each of which is incorporated by reference into this document.

Important U.S. notice

The Securities have not been and will not be registered under the U.S. Securities Act of 1933 (the "**Securities Act**"). Subject to certain exemptions, the Securities may not be offered, sold or delivered within the United States of America or to, or for the account or benefit of, U.S. persons. A further

description of the restrictions on offers and sales of the Securities in the United States or to U.S. persons is set forth in the section entitled "Selling Restrictions" of the Original CS Trigger Redeemable and Phoenix Securities Note and as supplemented by the Supplement dated 3 August 2021 to the Original CS Trigger Redeemable and Phoenix Securities Note, each of which is incorporated by reference into this document.

Taxation

Investors should be aware that the tax legislation of the country in which the investor is resident and of the Issuer's country of incorporation and in the country of the Issuer's branch that issues the Securities, may have an impact on the income received from the Securities.

Information only as at the date hereof

The delivery of this document at any time does not imply that any information contained herein is correct at any time subsequent to the date hereof.

No post-issuance information

The Issuer will not be providing any post-issuance information (save as set out herein), except if required by any applicable laws and regulations.

TABLE OF CONTENTS

	Page
IMPORTANT NOTICES	4
PART ONE	7
SUMMARY	7
PART TWO	14
SECURITIES NOTE.....	14
RISK FACTORS.....	14
DOCUMENTS INCORPORATED BY REFERENCE.....	16
SPECIFIC TERMS	18
GENERAL INFORMATION.....	34

PART ONE

SUMMARY

INTRODUCTION AND WARNINGS
<p>This Summary should be read as an introduction to the Prospectus. Any decision to invest in the Securities should be based on a consideration of the Prospectus as a whole by the investor. In certain circumstances, the investor could lose all or part of the invested capital. Where a claim relating to the information contained in the Prospectus is brought before a court, the plaintiff investor might, under the national law, have to bear the costs of translating the Prospectus before the legal proceedings are initiated. Civil liability attaches only to those persons who have tabled this Summary including any translation thereof, but only where this Summary is misleading, inaccurate or inconsistent, when read together with the other parts of the Prospectus or where it does not provide, when read together with the other parts of the Prospectus, key information in order to aid investors when considering whether to invest in the Securities.</p> <p><i>You are about to purchase a product that is not simple and may be difficult to understand.</i></p>
<p>The Securities</p> <p>USD 6,000,000 Trigger Yield Securities linked to a Share Basket, due October 2024 (ISIN: XS2387777555; Series Number: SPLB2021-1ZQP) (the "Notes" or the "Securities").</p>
<p>The Issuer</p> <p>The Issuer is Credit Suisse AG acting through its London Branch at One Cabot Square, London, E14 4QJ, United Kingdom and its Legal Entity Identifier (LEI) is ANGGYXNX0JLX3X63JN86.</p>
<p>Competent authority</p> <p>This Prospectus was approved on 17 November 2021 by the Luxembourg <i>Commission de Surveillance du Secteur Financier</i> of 283, route d'Arlon, L-1150 Luxembourg (Telephone number: (+352) 26 25 1-1; Fax number: (+352) 26 25 1-2601; Email: direction@cssf.lu).</p>
KEY INFORMATION ON THE ISSUER
Who is the Issuer of the Securities?
<p>Domicile and legal form, law under which the Issuer operates and country of incorporation</p> <p>Credit Suisse AG ("CS" or "Credit Suisse") (ANGGYXNX0JLX3X63JN86) is incorporated under Swiss law as a corporation (<i>Aktiengesellschaft</i>) and domiciled in Zurich, Switzerland and operates under Swiss law.</p>
<p>Issuer's principal activities</p> <p>The principal activities of CS are the provision of financial services in the areas of private banking, investment banking and asset management.</p>
<p>Major shareholders, including whether it is directly or indirectly owned or controlled and by whom</p> <p>CS is wholly owned by Credit Suisse Group AG.</p>
<p>Key managing directors</p> <p>The key managing directors of the Issuer are members of the Issuer's Executive Board. These are: Thomas Gottstein (Chief Executive Officer), Romeo Cerutti, Lydie Hudson, Ulrich Körner, Rafael Lopez Lorenzo, David R. Mathers, Christian Meissner, Joachim Oechslin, Antoinette Poschung, Helman Sitohang, James B. Walker and Philipp Wehle.</p>
<p>Statutory auditors</p> <p>CS's independent auditor and statutory auditor for the fiscal year ending 31 December 2020 was PricewaterhouseCoopers AG, Birchstrasse 160 8050 Zurich, Switzerland.</p> <p>CS's independent auditor and statutory auditor for the fiscal years ending 31 December 2019 and 31 December 2018 was KPMG AG, Râffelstrasse 28, 8045 Zurich, Switzerland.</p> <p>CS has mandated BDO AG, Fabrikstrasse 50, 8031 Zurich, as special auditor for the purposes of issuing the legally required report for capital increases in accordance with Article 652f of the Swiss Code of Obligations.</p>
What is the key financial information regarding the Issuer?
<p>CS derived the key financial information included in the tables below as of and for the years ended 31 December 2020, 2019 and 2018 from the Annual Report 2020, except where noted. The key financial information included in the tables below as of and for</p>

the nine months ended 30 September 2021 and 30 September 2020 was derived from the Form 6-K Dated 4 November 2021.

The consolidated financial statements were prepared in accordance with accounting principles generally accepted in the US ("US GAAP") and are stated in Swiss francs ("CHF").

CS consolidated statements of operations					
(CHF million)	Interim 9 months ended 30 September 2021 (unaudited)	Interim 9 months ended 30 September 2020 (unaudited)	Year ended 31 December 2020 (audited)	Year ended 31 December 2019 (audited)	Year ended 31 December 2018 (audited)
Net revenues	18,368	17,243	22,503	22,686	20,820
Of which: Net interest income	4,578	4,507	5,960	7,049	7,125
Of which: Commissions and fees	10,172	8,665	11,850	11,071	11,742
Of which: Trading revenues	2,523	2,710	3,178	1,773	456
Provision for credit losses	4,228	954	1,092	324	245
Total operating expenses	13,188	12,917	18,200	17,969	17,719
Of which: Commission expenses	959	953	1,256	1,276	1,259
Income before taxes	970	3,372	3,211	4,393	2,856
Net income attributable to shareholders	507	2,876	2,511	3,081	1,729

CS consolidated balance sheets			
(CHF million)	As of 30 September 2021 (unaudited)	As of 31 December 2020 (audited)	As of 31 December 2019 (audited)
Total assets	809,367	809,688	790,459
Of which: Net loans	305,047	300,341	304,025
Of which: Brokerage receivables	29,210	35,943	35,648
Total liabilities	759,067	762,629	743,696
Of which: Customer deposits	401,700	392,039	384,950
Of which: Short-term borrowings	23,935	21,308	28,869
Of which: Long-term debt	169,437	160,279	151,000

Of which: Brokerage payables	21,391	21,655	25,683
Total equity	50,300	47,059	46,763
Of which: Total shareholders' equity	49,549	46,264	46,120
Metrics (in %)			
Swiss CET1 ratio	16.3	14.7	14.4
Swiss TLAC ratio	37.9	35.3	32.6
Swiss TLAC leverage ratio	11.3	12.3	10.4

What are the key risks that are specific to the Issuer?

The Issuer is subject to the following key risks:

1. Liquidity risk arising from potential inability to borrow or access the capital markets on suitably favourable terms (including due to adverse changes in its credit ratings) or to sell its assets. This may also arise from increased liquidity costs. CS relies significantly on its deposit base for funding, which may not continue to be a stable source of funding over time.
2. Risks arising from the impact of market fluctuations and volatility on CS's investment activities (against which its hedging strategies may not prove effective). The spread of COVID-19 and resulting tight government controls and containment measures implemented around the world have caused severe disruption to global supply chains and economic activity, and the market has entered a period of significantly increased volatility. The spread of COVID-19 is continuing to have an adverse impact on the global economy, the severity and duration of which is difficult to predict, and has adversely affected CS's business, operations and financial performance. In addition, there can be no assurance that, even after adjustments are made to model outputs, Credit Suisse Group AG and its subsidiaries will not recognize unexpected losses arising from the uncertainty relating to its modelling for current expected credit losses that has resulted from the COVID-19 pandemic. The COVID-19 pandemic has significantly impacted, and is likely to continue to adversely affect CS's credit loss estimates, mark-to-market losses, trading revenues, net interest income and potential goodwill assessments, and may also adversely affect its ability to successfully realize its strategic objectives. To the extent the COVID-19 pandemic continues to adversely affect the global economy, and/or CS's business, operations or financial performance, it may also have the effect of increasing the likelihood and/or magnitude of other risks described herein, or may give rise to other risks not presently known to CS or not currently expected to be significant to its business, operations or financial performance. CS is closely monitoring the potential adverse effects and impact on its operations, businesses and financial performance, including liquidity and capital usage, though the extent of the impact is difficult to fully predict at this time due to the continuing evolution of this uncertain situation. CS is also exposed to other unfavourable economic, monetary, political, legal, regulatory and other developments in the countries in which it operates (as well as countries in which CS does not currently conduct business), including uncertainties regarding the expected discontinuation of benchmark rates. CS's significant positions in the real estate sector – and other large and concentrated positions – may also expose it to larger losses. Many of these market risk factors, including the impact of COVID-19, may increase other risks, including CS's credit risk exposures, which exist across a large variety of transactions and counterparties and in respect of which it may have inaccurate or incomplete information. These are exacerbated by adverse economic conditions and market volatility, including as a result of any defaults by large financial institutions (or any concerns relating thereto). The suspension and ongoing liquidation of certain supply chain finance funds and the failure of a US-based hedge fund to meet its margin commitments (and CS's exit from its positions relating thereto) may continue to have negative consequences for CS.
3. CS's ability to implement its current strategy, which is based on a number of key assumptions, is subject to various factors outside its control, including market and economic conditions and changes in law. The implementation of CS's strategy may increase its exposure to certain risks, including credit risks, market risks, operational risks and regulatory risks. The implementation of CS's strategy relating to acquisitions and other similar transactions subjects it to the risk that it may assume unanticipated liabilities (including legal and compliance issues), as well as difficulties relating to the integration of acquired businesses into its existing operations.
4. Country, regional and political risk in the regions in which CS has clients or counterparties, which may affect their ability to perform their obligations to CS. In part because an element of its strategy is to increase CS's private banking businesses in emerging market countries, it may face increased exposure to economic, financial and political disruptions in those countries, which could result in significant losses. Related fluctuations in exchange rates for currencies (particularly for the US dollar) may also adversely affect CS.
5. A wide variety of operational risks arising from inadequate or failed internal processes, people or systems or from external events, including breaches of cyber-security and other failures of information technology. CS relies heavily on financial, accounting and other data processing systems, which are varied and complex, and may face additional technology risks due to the global nature of its operations. CS is thereby exposed to risks arising from human error, negligence, employee misconduct, fraud, malice, accidental technology failure, cyber-attack and information or security breaches. This also exposes CS to risk from non-compliance with existing policies or regulations. Protecting against threats to CS's cyber-security and data protection systems requires significant financial and human resources. The ongoing global COVID-19 pandemic has increased the vulnerability of CS's information technology systems and the likelihood of damage as a result of a cybersecurity incident because of the wide-scale and prolonged shift to remote working for CS's employees and the increased reliance by CS's customers on remote (digital) banking services. CS's existing risk management procedures and policies

may not always be effective against such risks, particularly in highly volatile markets, and may not fully mitigate its risk exposure in all markets or against all types of risk. Moreover, CS's actual results may differ materially from its estimates and valuations, which are based upon judgment and available information and rely on predictive models and processes. The same is true of CS's accounting treatment of off-balance sheet entities, including special purpose entities, which requires it to exercise significant management judgment in applying accounting standards; these standards (and their interpretation) have changed and may continue to change. In addition, physical and transition climate risks could have a financial impact on CS either directly, through its physical assets, costs and operations, or indirectly, through its financial relationships with its clients.

6. CS's exposure to legal risks is significant and difficult to predict and the volume and amount of damages claimed in litigation, regulatory proceedings and other adversarial proceedings against financial services firms continues to increase in many of the principal markets in which CS operates. Changes in regulation (including in relation to sanctions) and monetary policy applicable to CS (as well as regulations and changes in enforcement practices applicable to its clients) may adversely affect its business and ability to execute its strategic plans and increase costs, as well as impact the demand from clients for CS's services. Moreover, CS's ability to attract and retain customers, clients, investors and employees, and conduct business transactions with its counterparties, could be adversely affected to the extent its reputation is damaged, which could arise from various sources, including if its procedures and controls fail (or appear to fail). In addition, Swiss resolution proceedings may affect CS's shareholders and creditors.
7. CS faces intense competition in all financial services markets, which has increased as a result of consolidation, as well as emerging technology and new trading technologies (including trends towards direct access to automated and electronic markets and the move to more automated trading platforms). In such a highly competitive environment, CS's performance is affected by its ability to recruit and retain highly skilled employees.

KEY INFORMATION ON THE SECURITIES

What are the main features of the Securities?

Type, class and security identification number(s): The Securities of a Series are notes in bearer form governed by English law and will be uniquely identified by **ISIN:** XS2387777555; **Common Code:** 238777755; **Series Number:** SPLB2021-1ZQP.

Currency, nominal amount/denomination, aggregate nominal amount and term of the Securities:

The currency of the Securities will be United States dollar ("**USD**"). The nominal amount (the "**Nominal Amount**") or specified denomination (the "**Specified Denomination**") per Security is USD 1,000. USD 6,000,000 in aggregate nominal amount of Securities will be issued.

The term of the Securities is from the issue date to the Maturity Date. The scheduled maturity date (the "**Maturity Date**") of the Securities shall be 5 currency business days following the Final Fixing Date (expected to be 15 October 2024).

Rights attached to the Securities: The Securities will give each holder of Securities (a "**Securityholder**") the right to receive the following:

- the Interest Amount(s) payable;
- the potential payment of a Trigger Barrier Redemption Amount following the occurrence of a Trigger Event; and
- the payment of the Redemption Amount on the Maturity Date.

INTEREST AMOUNT(S)

The Securities shall bear interest at USD 23 per Security. Interest will accrue from, and including, the issue date to, but excluding, the Maturity Date, such interest being payable in arrear on each Interest Payment Date. The "Interest Payment Dates" are each of 14 January 2022, 14 April 2022, 14 July 2022, 17 October 2022, 17 January 2023, 17 April 2023, 14 July 2023, 16 October 2023, 16 January 2024, 15 April 2024, 15 July 2024 and 15 October 2024.

TRIGGER BARRIER REDEMPTION AMOUNT

If a Trigger Event occurs, the Issuer shall redeem the Securities on the Trigger Barrier Redemption Date at the Trigger Barrier Redemption Amount in respect of such Trigger Barrier Redemption Date. For the avoidance of doubt, upon the occurrence of a Trigger Event, no Redemption Amount shall be payable after such Trigger Barrier Redemption Date.

Where:

	Trigger Barrier Observation Date_n	Trigger Barrier_n
1.	7 April 2022	97 per cent. of the relevant Strike Price
2.	7 July 2022	94 per cent. of the relevant Strike Price
3.	7 October 2022	91 per cent. of the relevant Strike Price

4.	7 January 2023	88 per cent. of the relevant Strike Price
5.	7 April 2023	85 per cent. of the relevant Strike Price
6.	7 July 2023	82 per cent. of the relevant Strike Price
7.	7 October 2023	79 per cent. of the relevant Strike Price
8.	7 January 2024	76 per cent. of the relevant Strike Price
9.	7 April 2024	73 per cent. of the relevant Strike Price
10.	7 July 2024	70 per cent. of the relevant Strike Price
11.	7 October 2024	70 per cent. of the relevant Strike Price

- **Trigger Barrier Redemption Amount:** 100 per cent. of the Nominal Amount.
- **Trigger Barrier Redemption Date(s):** 5 currency business days following the occurrence of a Trigger Event.
- **Trigger Event:** if on the relevant Trigger Barrier Observation Date, the Level of each underlying asset at the Valuation Time is at or above the Trigger Barrier of such underlying asset.
- **Valuation Time:** the scheduled closing time on the relevant exchange.

REDEMPTION AMOUNT

The Issuer shall redeem the Securities on the Maturity Date at the redemption amount (the "**Redemption Amount**") determined in accordance with paragraph (a) or (b) below:

- (a) if a Knock-in Event has occurred, the *product* of (i) the Nominal Amount and (ii) the Worst Final Price *divided* by Worst Redemption Strike Price, subject to a maximum amount equal to 100 per cent. of the Nominal Amount; or
- (b) if no Knock-in Event has occurred, the *product* of (i) the Nominal Amount and (ii) 100 per cent.

If a Trigger Event occurs on the Knock-in Observation Date, then no Redemption Amount shall be payable and the Securities will be redeemed pursuant to "Trigger Barrier Redemption Amount" above.

Where:

- **Level:** the closing level of the relevant underlying asset quoted on the relevant exchange.
- **Initial Setting Date:** 7 October 2021.
- **Final Fixing Date:** 7 October 2024.
- **Final Price:** the Level of the relevant underlying asset at the Valuation Time on the Final Fixing Date.
- **Knock-in Barrier:** 65 per cent. of the relevant Strike Price.
- **Knock-in Event:** if on the Knock-in Observation Date, the Level of the Second Worst Performing Underlying Asset at the Valuation Time is below the Knock-in Barrier of such underlying asset, provided that if a Knock-out Event has occurred on the Knock-out Observation Date, then no Knock-in Event shall be deemed to have occurred.
- **Knock-in Observation Date:** 7 October 2024.
- **Knock-out Barrier:** 130 per cent. of the relevant Strike Price.
- **Knock-out Event:** if on the Knock-out Observation Date, the Level of any underlying asset at the Valuation Time is at or above the Knock-out Barrier of such underlying asset.
- **Knock-out Observation Date:** 7 October 2024.
- **Redemption Strike Price:** 65 per cent. of the relevant Strike Price.
- **Second Worst Performing Underlying Asset:** the underlying asset with the second lowest Underlying Asset Return.

- **Strike Price:** the Level of the relevant underlying asset at the Valuation Time on the Initial Setting Date.
- **Worst Final Price:** the Final Price of the Worst Performing Underlying Asset.
- **Worst Redemption Strike Price:** the Redemption Strike Price of the Worst Performing Underlying Asset.
- **Worst Performing Underlying Asset:** the underlying asset with the lowest Underlying Asset Return.
- **Underlying Asset Return:** in respect of an underlying asset, (a) the Final Price of such underlying asset, *divided* by (b) its Strike Price.

Adjustments to valuation and payment dates: Dates on which the underlying asset(s) are scheduled to be valued or on which payments are scheduled to be made may be subject to adjustment for non-underlying asset days, disruptions or non-business days in accordance with the conditions of the Securities.

Underlying asset(s): The underlying assets to which the Securities are linked are (a) the ordinary shares of Arrowhead Pharmaceuticals Inc (ISIN: US04280A1007; Bloomberg Code: ARWR UW <Equity>) (the "**Arrowhead Pharmaceuticals Shares**"), (b) the ordinary shares of Ultragenyx Pharmaceutical Inc (ISIN: US90400D1081; Bloomberg Code: RARE UW <Equity>) (the "**Ultragenyx Pharmaceutical Shares**"), (c) the ordinary shares of Invitae Corporation (ISIN: US46185L1035; Bloomberg Code: NVTA UN <Equity>) (the "**Invitae Shares**"), and (d) the ordinary shares of CRISPR Therapeutics AG (ISIN: CH0334081137; Bloomberg Code: CRSP UQ <Equity>) (the "**CRISPR Therapeutics Shares**").

Information on the underlying assets can be found free of charge at: (i) in respect of each of the Arrowhead Pharmaceuticals Shares, the Ultragenyx Pharmaceutical Shares and the CRISPR Therapeutics Shares, <https://www.nasdaq.com>, and (ii) in respect of the Invitae Shares, <https://www.nyse.com>.

Status of the Securities: The Securities are unsubordinated and unsecured obligations of the Issuer and will rank equally among themselves and with all other unsubordinated and unsecured obligations of the Issuer from time to time outstanding.

Description of restrictions on free transferability of the Securities: The Securities are freely transferable (subject to all applicable laws).

Where will the Securities be traded?

Application has been made to admit the Securities to trading on the regulated market of the Luxembourg Stock Exchange.

What are the key risks that are specific to the Securities?

The Securities are subject to the following key risks:

1. **Risks in case of an insolvency or resolution measures in respect of the Issuer.** An investment in the Securities constitutes unsecured obligations of the Issuer and will not be covered by any statutory or other deposit protection scheme and does not have the benefit of any guarantee. Therefore in the event of the insolvency of the Issuer, an investor in the Securities may lose all or some of its investment therein irrespective of any favourable development of the other value determining factors, such as the performance of the underlying asset(s). Similarly, prior to an insolvency of the Issuer, rights of the holders of the Securities may be adversely affected by the Swiss Financial Market Supervisory Authority FINMA's broad statutory powers in the case of a restructuring proceeding in relation to Credit Suisse, including its power to convert the Securities into equity and/or partially or fully write-down the Securities.
2. **Potential loss of some or all of the investment.** The Securities are "capital at risk" investments and investors may lose some or all of their money depending on the performance of the relevant underlying asset(s). If the underlying asset(s) fails to meet the specified threshold or barrier or if the amount payable on redemption of the Securities is less than the purchase price paid by investors for the Securities, investors could lose some or all of their investment. In addition, if the Securities are sold in the secondary market for less than the purchase price paid by the relevant investor, investors could lose some or all of their investment.
3. **Risks in connection with redemption of the Securities at the unscheduled termination amount.** The Securities may be redeemed at the unscheduled termination amount in certain circumstances, including: following the occurrence of an event of default or for illegality reasons or following certain events affecting the Issuer's hedging arrangements and/or the underlying asset(s). In such circumstances, the unscheduled termination amount is likely to be less than the original purchase price and could be as low as zero and, following any such early redemption, investors may be unable to reinvest the proceeds in an investment having a comparable return. Following the occurrence of any such event, no other amounts on account of interest or otherwise shall be payable by the Issuer in respect of the Securities.
4. **Risks in connection with discretionary rights of the Calculation Agent and related termination rights of the Issuer.** Upon the occurrence of an adjustment event or an extraordinary event, the Issuer or Calculation Agent has broad discretion to make certain modifications to the terms and conditions of the Securities to account for such event, without the consent of the Securityholders, including but not limited to, adjusting the calculation of the value of any underlying asset or any amount payable or other benefit to be received under the Securities, or substituting any underlying asset. Any such adjustment, postponement, alternative valuation or substitution could have a material adverse effect on the return on, and value of, the Securities and shall be made without the consent of the Securityholders.

5. **Early redemption following a Trigger Event.** As the Securities have a trigger feature, the timing of redemption of the Securities is uncertain as the occurrence of a Trigger Event will be dependent on the performance of the underlying asset(s). In the case of an unfavourable development of the value of the underlying asset(s), any redemption may only occur on the scheduled maturity date and the amount payable on redemption of the Securities will be determined based on the unfavourable performance of the underlying asset(s). In such circumstances, the return on the Securities may be less than the amount originally invested and less than an investor would have received had a Trigger Event occurred.
6. **"Worst-of".** Securityholders will be exposed to the performance of the underlying assets which have the worst performance and the second worst performance of a basket of underlying assets, unless a Knock-out Event has occurred. Therefore, if the underlying asset having the second worst performance fails to meet the specified threshold or barrier, and no Knock-out Event has occurred, investors could lose some or all of their initial investment as the amount payable will be based on the performance of the underlying asset with the worst performance.
7. **Risks associated with shares.** The performance of a share is dependent upon macroeconomic factors which may adversely affect such performance and, in turn, the value of the Securities. The issuer of a share has no obligation to any Securityholder and may take any actions in respect of such share without regard to the interests of Securityholders which could adversely affect the market value of and return on the Securities.
8. **Risks in connection with the secondary market.** The secondary market for the Securities may be limited, may never develop at all or may not continue even though the Securities are listed, which may adversely impact the market value of such Securities or the ability of the investor thereof to sell such Securities. In addition, the market value of the Securities will be affected by factors beyond the control of the Issuer, such as the creditworthiness of the Issuer, the remaining time to maturity of the Securities, interest and yield rates, the value and volatility of the underlying asset(s), the occurrence of certain events in relation to the underlying asset(s) and national and international events.

KEY INFORMATION ON THE OFFER OF THE SECURITIES TO THE PUBLIC AND THE ADMISSION TO TRADING ON A REGULATED MARKET

Under which conditions and timetable can I invest in this Security?

Issue/offer of the Securities: The Securities have been offered to the dealer at the issue price of 100 per cent. of the aggregate nominal amount. The Securities are not being publicly offered.

Issue date and admission to trading: The issue date of the Securities is 22 October 2021 and application has been made for the Securities to be admitted to trading on or around the issue date.

Estimated total expenses of the issue/offer, including estimated expenses charged to the purchaser by the Issuer/offeror

There are no estimated expenses charged to the purchaser by the Issuer and the distributor(s).

The Securities will be sold by Credit Suisse Bank (Europe), S.A. (as an intermediary between the dealer and each distributor) ("CSEB") to the distributor(s) at a discount of up to 6 per cent. of the issue price per Security. Such discount represents the fee retained by the distributor(s) out of the issue price paid by investors, equivalent to approximately 2 per cent. per annum of the Specified Denomination per Security.

Who is the offeror and/or the person asking for admission to trading?

The Issuer is the entity requesting for the admission to trading of the Securities.

Why is this Prospectus being produced?

Reasons for the issue/offer, estimated net proceeds and use of proceeds:

The net proceeds from the issue of the Securities, which are expected to amount to USD 6,000,000, will be used by the Issuer for its general corporate purposes (including hedging arrangements).

Underwriting agreement on a firm commitment basis:

The offer of the Securities is not subject to an underwriting agreement on a firm commitment basis.

Material conflicts pertaining to the issue/offer:

Fees are payable to the distributor(s). In making calculations and determinations with regard to the Securities, there may be a difference of interest between the Securityholders and the Issuer, the dealer, CSEB (either on its own or as an intermediary between the dealer and each distributor) and their affiliated entities. In particular, the Issuer, the dealer, CSEB and their affiliated entities may have interests in other capacities (such as other business relationships and activities) and when acting in such other capacities may pursue actions and take steps that they deem necessary to protect their interests without regard to the consequences for any particular Securityholder, which may have a negative impact on the value of and return on the Securities. In the ordinary course of its business, the Issuer, the dealer, CSEB and/or any of their affiliates may effect transactions in relation to underlying asset(s) and may enter into one or more hedging transactions with respect to the Securities. Such activities may affect the market price, liquidity, value of or return on the Securities and could be adverse to the interest of the relevant Securityholders.

PART TWO
SECURITIES NOTE
RISK FACTORS

The Issuer believes that the risk factors specific to the Securities described below are material for the purpose of taking an informed investment decision associated with the Securities, but these are not the only risks that the Issuer faces or that may arise under the Securities. There will be other risks that the Issuer does not currently consider to be material, or risks that the Issuer is currently not aware of, or risks that arise due to circumstances specific to the investor.

Investing in the Securities involves certain risks, including that an investor may lose some or all of their investment in certain circumstances. More than one investment risk may have simultaneous effect with regard to the value of the Securities and the effect of any single investment risk may not be predictable. In addition, more than one investment risk may have a compounding effect and no assurance can be given as to the effect that any combination of investment risks may have on the value of Securities.

For a description of the risk factors relating to the Issuer, investors should refer to the Registration Document for the Issuer, where the specific risks associated with the Issuer are set out. An investment in Securities entails certain risks, which vary depending on the specific type and structure of the relevant Security and the relevant Underlying Asset(s) which the Security is linked to. The risk factor that the Issuer considers most material to an investment decision is presented first in each category.

Risks relating to the Securities

See the section entitled "Risk Factors" contained on pages 21 to 72 of the Original CS Trigger Redeemable and Phoenix Securities Note, as supplemented by the Supplement dated 3 August 2021 to the Original CS Trigger Redeemable and Phoenix Securities Note, which are incorporated by reference into this Securities Note. In particular, investors should have regard to the risks described under the following category and sub-category headings set out in the Securities Note, which the Issuer considers to be material to an investment in the Securities:

1. **Risks associated with Securities in case of insolvency of the Issuer and in connection with resolution measures in respect of the Issuer (Risk Category 1) (pages 21 and 22 of the Original CS Trigger Redeemable and Phoenix Securities Note):**
 - (a) Risk in case of an insolvency of the Issuer; and
 - (b) Risks related to FINMA's broad statutory powers in relation to CS;
2. **Risks in connection with the payment profile of the Securities (Risk Category 2) (pages 22 and 23 of the Original CS Trigger Redeemable and Phoenix Securities Note):**

Potential loss of some or all of the investment;
3. **Risks in connection with termination and adjustment rights of the Issuer and/or the Calculation Agent (Risk Category 3) (pages 23 to 29 of the Original CS Trigger Redeemable and Phoenix Securities Note):**
 - (a) Risks in connection with redemption of the Securities at the Unscheduled Termination Amount;
 - (b) Risks in connection with discretionary rights of the Calculation Agent and related termination rights of the Issuer;
 - (c) The Issuer of Securities may be substituted without the consent of Securityholders;
 - (d) Occurrence of Additional Disruption Events;
 - (e) Correction of published prices or levels; and

- (f) Non-Underlying Asset Days or disruption events may adversely affect the value of and return on the Securities;
4. **Risks related to certain types of Securities and certain product features (Risk Category 4) (pages 29, 31 to 32 and 34 of the Original CS Trigger Redeemable and Phoenix Securities Note):**
- (a) "Worst-of", provided that the first two paragraphs shall be deleted in their entirety and replaced with the following:

"Securityholders will be particularly exposed to the performance of the Underlying Assets which have the worst performance and the second worst performance of the Share Basket, unless a Knock-out Event has occurred.

This means that, if the Underlying Asset having the second worst performance fails to meet the specified threshold or barrier, and no Knock-out Event has occurred, Securityholders could lose some or all of their initial investment as the amount payable will be based on the performance of the Underlying Asset with the worst performance.";
 - (b) Risks of Securities with barrier feature(s);
 - (c) Early Redemption following a Trigger Event; and
 - (d) Interest rate risks;
5. **Risks in connection with the Underlying Assets or Reference Rates (Risk Category 5) (page 34 to 36 of the Original CS Trigger Redeemable and Phoenix Securities Note):**
- (a) Risks associated with Shares (including Depositary Receipts and stapled shares);
6. **Risks in connection with the purchase, holding and selling of Securities (Risk Category 6) (pages 66 to 70, 72 of the Original CS Trigger Redeemable and Phoenix Securities Note):**
- (a) Risks related to fluctuation in the market value of the Securities;
 - (b) Risks in connection with the secondary market in general;
 - (c) Risks in connection with a listing of Securities;
 - (d) Risks of Securities with an Issue Price or Offer Price above the market value of the Securities on the issue date/payment date;
 - (e) Risks in connection with conflicts of interest between the Issuer and holders of Securities and the entities involved in the offer or listing of the Securities;
 - (f) Hedging and dealing activities in relation to the Securities and the Underlying Asset(s);
 - (g) Risk in connection with taxes or other charges that are levied in respect of the Securities;
 - (h) Risk in connection with transaction costs/charges; and
 - (i) Inflation risk.

DOCUMENTS INCORPORATED BY REFERENCE

This Prospectus should be read and construed in conjunction with (a) the Original CS Trigger Redeemable and Phoenix Securities Note and (b) the Supplement dated 3 August 2021 to the Original CS Trigger Redeemable and Phoenix Securities Note, except the documents incorporated by reference therein and to the extent of the information to be incorporated by reference as provided below, which shall be deemed to be incorporated by reference in, and form part of this Prospectus, save that any statement contained in the Original CS Trigger Redeemable and Phoenix Securities Note and the Supplement dated 3 August 2021 to the Original CS Trigger Redeemable and Phoenix Securities Note shall be deemed to be modified or superseded for the purpose of this Prospectus to the extent that a statement contained herein modifies or supersedes such earlier statement (whether expressly, by implication or otherwise). Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Prospectus.

The table below sets out the relevant page references for the information incorporated into this Prospectus by reference.

	Page reference
Original CS Trigger Redeemable and Phoenix Securities Note (which can be accessed at: https://derivative.credit-suisse.com/ux/gb/en/document/get/id/98DD39C1-3C3A-4D26-AEB8-7D205ADC6D86)	
Risk Factors	21 to 72
Use of Proceeds	93
Overview of the Potential for Discretionary Determinations by the Issuer	94 to 105
Overview of Provisions relating to Notes while in Global Form	106 to 107
General Terms and Conditions of Notes	108 to 141
Product Conditions	233 to 288
Asset Terms for Equity-linked Securities	289 to 305
Clearing Arrangements	623 to 624
Taxation	627 to 675
Selling Restrictions	677 to 690
Supplement dated 3 August 2021 to the Original CS Trigger Redeemable and Phoenix Securities Note (which can be accessed at: https://derivative.credit-suisse.com/ux/gb/en/document/get/id/992E5BDE-9755-433E-B636-850880665649)	
Amendment to the section entitled "Risk Factors" in each Securities Note (as such amendments relate to the CS Trigger Redeemable and Phoenix Securities Note)	2
Amendment to the section entitled "Product Conditions" in each Securities Note (as such amendments relate to the CS Trigger Redeemable and Phoenix Securities Note)	2 to 4
Amendment to the section entitled "Selling Restrictions" in each Securities Note (as such amendments relate to the CS Trigger Redeemable and Phoenix Securities Note)	10

For the avoidance of doubt, any information not incorporated by reference from the CS Trigger Redeemable and Phoenix Securities Note is not relevant for the investor in respect of the Securities or is otherwise covered elsewhere in this Prospectus.

Copies of the Prospectus (consisting of this Summary and Securities Note and the Registration Document) and the documents incorporated by reference are available on the website of the Luxembourg Stock Exchange (www.bourse.lu) and the website of the Issuer (<https://derivative.credit-suisse.com>).

Investors who have not previously reviewed the information incorporated by reference in this Prospectus from the CS Trigger Redeemable and Phoenix Securities Note and the Registration Document should do so in connection with their evaluation of the Securities.

Terms defined in the General Conditions, the Product Conditions or the Asset Terms shall have the same meaning herein unless otherwise defined in the Specific Terms (as defined below).

In the event of any inconsistency between (a) the Specific Terms and (b) the General Conditions, the Product Conditions or the Asset Terms, the Specific Terms will prevail.

SPECIFIC TERMS

The Securities will be subject to the General Conditions, the Product Conditions and the Asset Terms (in each case, as defined and incorporated by reference in "Documents Incorporated by Reference" above and as set out in the CS Trigger Redeemable and Phoenix Securities Note (as incorporated by reference herein), and also to the following provisions (the "**Specific Terms**"). Each reference in such General Conditions, Product Conditions and Asset Terms to the "Issue Terms" shall be deemed to be deleted and replaced by the "Specific Terms".

In the event of any inconsistency between the General Conditions, the Product Conditions, the Asset Terms and the Specific Terms, the prevailing terms will be determined in accordance with the following order of priority (where (a) prevails over the other terms): (a) the Specific Terms, (b) the Product Conditions, (c) the Asset Terms, and (d) the General Conditions.

PART A – CONTRACTUAL TERMS

1. Series Number: SPLB2021-1ZQP
2. Tranche Number: Not Applicable
3. Applicable General Terms and Conditions: General Note Conditions
4. Type of Security: Trigger Yield Securities
5. Settlement Currency: United States dollar ("**USD**")
6. Institutional: Applicable

PROVISIONS RELATING TO NOTES AND CERTIFICATES

7. Aggregate Nominal Amount: Applicable
 - (i) Series: USD 6,000,000
 - (ii) Tranche: Not Applicable
8. Issue Price: 100 per cent. of the Aggregate Nominal Amount
9. Specified Denomination: USD 1,000
10. Minimum Transferable Number of Securities: Not Applicable
11. Transferable Number of Securities: Not Applicable
12. Minimum Trading Lot: Not Applicable
13. Issue Date: 22 October 2021
14. Maturity Date: 5 Currency Business Days following the Final Fixing Date (expected to be 15 October 2024)
15. Coupon Basis: Applicable: Fixed Rate Provisions
16. Redemption/Payment Basis: Equity-linked
17. Put/Call Options: Not Applicable

PROVISIONS RELATING TO WARRANTS Not Applicable

(Paragraphs 18 to 28 have been intentionally deleted)

PROVISIONS RELATING TO COUPON AMOUNTS

29. Fixed Rate Provisions (General Note Condition 4 or General Certificate Condition 4): Applicable
- (i) Rate(s) of Interest: Not Applicable
 - (ii) Interest Commencement Date: Issue Date
 - (iii) Interest Payment Date(s): Each of 14 January 2022, 14 April 2022, 14 July 2022, 17 October 2022, 17 January 2023, 17 April 2023, 14 July 2023, 16 October 2023, 16 January 2024, 15 April 2024, 15 July 2024 and 15 October 2024, in each case, subject to adjustment in accordance with the Business Day Convention
 - (iv) Interest Period: Not Applicable
 - (v) Business Day Convention: Following Business Date Convention
 - (vi) Interest Amount(s) per Security: USD 23 per Specified Denomination
 - (vii) Day Count Fraction: Not Applicable
 - (viii) Determination Date(s): Not Applicable
 - (ix) Trade Date: 7 October 2021
30. Floating Rate Provisions (General Note Condition 4 or General Certificate Condition 4): Not Applicable
31. Premium Provisions (General Note Condition 4 or General Certificate Condition 4): Not Applicable
32. Other Coupon Provisions (Product Condition 2): Not Applicable

PROVISIONS RELATING TO REDEMPTION/SETTLEMENT

33. Redemption Amount (Product Condition 3): Worst of Trigger Redeemable
- (i) Redemption Option Percentage: Applicable: 100 per cent.
 - (ii) Redemption Performance: Not Applicable
 - (iii) Redemption Amount Cap/Floor: Applicable
 - Redemption Amount Cap 1: An amount equal to 100 per cent. of the Nominal Amount

	–	Redemption Amount Floor 1:		Not Applicable
	–	Redemption Amount Cap 2:		Not Applicable
	–	Redemption Amount Floor 2:		Not Applicable
(iv)		Redemption Strike Price:		In respect of an Underlying Asset, an amount equal to 65 per cent. of the Strike Price of such Underlying Asset
(v)		Redemption Adjustment:	FX	Not Applicable
(vi)		PPT:		Not Applicable
(vii)		Strike:		Not Applicable
(viii)		Nth (for the purposes of determining the Worst Performing Underlying Asset):		1st lowest (i.e. the lowest) as specified in Product Condition 1
34.		Initial Setting Date:		7 October 2021
35.		Initial Averaging Dates:		Not Applicable
36.		Final Fixing Date:		7 October 2024
37.		Averaging Dates:		Not Applicable
38.		Final Price:		In respect of an Underlying Asset, the Level (with regard to the Valuation Time) of such Underlying Asset on the Final Fixing Date
	(i)	Final Price Cap:		Not Applicable
	(ii)	Final Price Floor:		Not Applicable
39.		Strike Price:		In respect of an Underlying Asset, the Level (with regard to the Valuation Time) of such Underlying Asset on the Initial Setting Date
	(i)	Strike Cap:		Not Applicable
	(ii)	Strike Floor:		Not Applicable
40.		Knock-in Provisions:		Applicable, as amended herein
	(i)	Knock-in Event:		On the Knock-in Observation Date, the Level (with regard to the Valuation Time) of the Second Worst Performing Underlying Asset is below the Knock-in Barrier of such Underlying Asset, where " Second Worst Performing Underlying Asset " means the Underlying Asset with the second lowest Underlying Asset Return, as determined by the Calculation Agent. The definition of "Knock-in Event" in Product Condition 3(b)(iii) shall be deemed to be amended accordingly
	(ii)	Knock-in Barrier:		In respect of the Knock-in Observation Date and an Underlying Asset, an amount equal to 65 per cent. of the

			Strike Price of such Underlying Asset
(iii)	Knock-in Date(s):	Observation	7 October 2024
(iv)	Knock-in Date subject to Date adjustment:	Observation Valuation Date adjustment:	Valuation Date adjustment applicable in respect of the Knock-in Observation Date
(v)	Knock-in Period:	Observation	Not Applicable
(vi)	Knock-in Fixing Price:		Not Applicable
(vii)	Redemption Participation:		Not Applicable
(viii)	Floor:		Not Applicable
(ix)	Knock-out Event Condition:	Override	Applicable
41.	Knock-out Provisions:		Applicable
(i)	Knock-out Event:		On the Knock-out Observation Date, the Level (at the Valuation Time) of any Underlying Asset is at or above the Knock-out Barrier of such Underlying Asset
(ii)	Knock-out Barrier:		In respect of the Knock-out Observation Date and an Underlying Asset, an amount equal to 130 per cent of the Strike Price of such Underlying Asset
(iii)	Knock-out Date(s):	Observation	7 October 2024
(iv)	Knock-out Date subject to Date adjustment:	Observation Valuation Date adjustment:	Valuation Date adjustment applicable in respect of the Knock-out Observation Date
(v)	Knock-out Period:	Observation	Not Applicable
(vi)	Knock-out Fixing Price:		Not Applicable
42.	Trigger Redemption Condition 3(c):	(Product	Applicable
(i)	Trigger Event:	Barrier	On any Trigger Barrier Observation Date, the Level of each Underlying Asset is at or above the Trigger Barrier of such Underlying Asset
(ii)	Trigger Redemption Date(s):	Barrier Observation Date(s):	In respect of a Trigger Barrier Observation Date, as specified in the table below in respect of such Trigger Barrier Observation Date
(iii)	Trigger Redemption Amount:	Barrier Redemption Date:	In respect of a Trigger Barrier Redemption Date, as specified in the table below in respect of such Trigger Barrier Redemption Date
(iv)	Trigger Barrier:		In respect of a Trigger Barrier Observation Date and an Underlying Asset, as specified in the table below in respect of such Trigger Barrier Observation Date

10.	7 July 2024	An amount equal to 70 per cent. of the Strike Price of such Underlying Asset	An amount equal to 100 per cent. of the Nominal Amount	5 Currency Business Days following the occurrence of a Trigger Event
11.	7 October 2024	An amount equal to 70 per cent. of the Strike Price of such Underlying Asset	An amount equal to 100 per cent. of the Nominal Amount	5 Currency Business Days following the occurrence of a Trigger Event
	(viii)	Knock-in Event Override Condition:	Not Applicable	
	(ix)	Trigger Barrier Fixing Price:	Not Applicable	
	(x)	Trigger Coupon Override Condition:	Not Applicable	
	(xi)	Trigger Knock-out Barrier:	Not Applicable	
	(xii)	Trigger Knock-out Event:	Not Applicable	
	(xiii)	Trigger Knock-out Observation Period Start Date(s):	Not Applicable	
	(xiv)	Trigger Knock-out Observation Period End Date(s):	Not Applicable	
43.	Lock-in Redemption:		Not Applicable	
44.	Single Factor Trigger Redeemable (Step-Up) / Single Factor Trigger Redeemable (Star) / Worst of Trigger Redeemable (Step-Up) / Worst of Trigger Redeemable (Star):		Not Applicable	
45.	Knock-in Put Spread:		Not Applicable	
46.	Details relating to Instalment Securities:		Not Applicable	
47.	Physical Settlement Provisions (Product Condition 4):		Not Applicable	
48.	Put Option:		Not Applicable	
49.	Call Option:		Not Applicable	
50.	Unscheduled Termination Amount:			
	(i)	Unscheduled Termination at Par:	Not Applicable	
	(ii)	Minimum Payment Amount:	Not Applicable	
	(iii)	Deduction for Hedge	Not Applicable	

Costs:

51. Payment Disruption: Not Applicable
52. Interest and Currency Rate Additional Disruption Event: Not Applicable
53. Dividend Adjusted Performance: Not Applicable

UNDERLYING ASSET(S)

54. List of Underlying Asset(s): Applicable
- | i | Underlying Asset_i | Weight_i | Composite_i |
|----------|--|---------------------------|------------------------------|
| 1. | The ordinary shares of Arrowhead Pharmaceuticals Inc (the " Arrowhead Pharmaceuticals Shares ") | Not Applicable | Not Applicable |
| 2. | The ordinary shares of Ultragenyx Pharmaceutical Inc (the " Ultragenyx Pharmaceutical Shares ") | Not Applicable | Not Applicable |
| 3. | The ordinary shares of Invitae Corporation (the " Invitae Shares ") | Not Applicable | Not Applicable |
| 4. | The ordinary shares of CRISPR Therapeutics AG (the " CRISPR Therapeutics Shares ") | Not Applicable | Not Applicable |
55. Equity-linked Securities: Applicable
- Single Share, Share Basket or Multi-Asset Basket: Share Basket

In respect of the Arrowhead Pharmaceuticals Shares:

- (i) Share Issuer: Arrowhead Pharmaceuticals Inc
- (ii) Share: The Arrowhead Pharmaceuticals Shares
- (iii) ISIN: US04280A1007
- (iv) Bloomberg Code: ARWR UW <Equity>
- (v) Information Source: <https://www.nasdaq.com>
- (vi) Exchange: NASDAQ
- (vii) Related Exchange: All Exchanges
- (viii) Maximum Days of Disruption: Eight Scheduled Trading Days as specified in Asset Term 1
- (ix) Adjustment basis for Share Basket and Reference Dates: In respect of the Initial Setting Date, each Trigger Barrier Observation Date, the Knock-in Observation Date, the Knock-out Observation Date and the Final Fixing Date: Share Basket and Reference Dates –

Individual/Individual

- (x) Adjustment basis for Share Basket and Averaging Reference Dates: Not Applicable
- (xi) Trade Date: 7 October 2021
- (xii) Jurisdictional Event: Not Applicable
- (xiii) Jurisdictional Event Jurisdiction(s): Not Applicable
- (xiv) Share Substitution: Applicable
- (xv) Additional Disruption Events:
 - (a) Change in Law: Change in Law Option 1 Applicable
 - (b) Change of Exchange: Applicable
 - (c) Foreign Ownership Event: Not Applicable
 - (d) FX Disruption: Not Applicable
 - (e) Insolvency Filing: Applicable
 - (f) Hedging Disruption: Applicable
 - (g) Increased Cost of Hedging: Not Applicable
 - (h) Loss of Stock Borrow: Not Applicable
 - (i) Increased Cost of Stock Borrow: Not Applicable
- (xvi) Dividend Adjusted Performance: Not Applicable

In respect of the Ultragenyx Pharmaceutical Shares:

- (i) Share Issuer: Ultragenyx Pharmaceutical Inc
- (ii) Share: The Ultragenyx Pharmaceutical Shares
- (iii) ISIN: US90400D1081
- (iv) Bloomberg Code: RARE UW <Equity>
- (v) Information Source: <https://www.nasdaq.com>
- (vi) Exchange: NASDAQ
- (vii) Related Exchange: All Exchanges
- (viii) Maximum Days of Eight Scheduled Trading Days as specified in Asset Term

- Disruption: 1
- (ix) Adjustment basis for Share Basket and Reference Dates: In respect of the Initial Setting Date, each Trigger Barrier Observation Date, the Knock-in Observation Date, the Knock-out Observation Date and the Final Fixing Date: Share Basket and Reference Dates – Individual/Individual
- (x) Adjustment basis for Share Basket and Averaging Reference Dates: Not Applicable
- (xi) Trade Date: 7 October 2021
- (xii) Jurisdictional Event: Not Applicable
- (xiii) Jurisdictional Event Jurisdiction(s): Not Applicable
- (xiv) Share Substitution: Applicable
- (xv) Additional Disruption Events:
- (a) Change in Law: Change in Law Option 1 Applicable
- (b) Change of Exchange: Applicable
- (c) Foreign Ownership Event: Not Applicable
- (d) FX Disruption: Not Applicable
- (e) Insolvency Filing: Applicable
- (f) Hedging Disruption: Applicable
- (g) Increased Cost of Hedging: Not Applicable
- (h) Loss of Stock Borrow: Not Applicable
- (i) Increased Cost of Stock Borrow: Not Applicable
- (xvi) Dividend Adjusted Performance: Not Applicable

In respect of the Invitae Shares:

- (i) Share Issuer: Invitae Corporation
- (ii) Share: The Invitae Shares
- (iii) ISIN: US46185L1035
- (iv) Bloomberg Code: NVTA UN <Equity>

- (v) Information Source: <https://www.nyse.com>
- (vi) Exchange: New York Stock Exchange
- (vii) Related Exchange: All Exchanges
- (viii) Maximum Days of Disruption: Eight Scheduled Trading Days as specified in Asset Term 1
- (ix) Adjustment basis for Share Basket and Reference Dates: In respect of the Initial Setting Date, each Trigger Barrier Observation Date, the Knock-in Observation Date, the Knock-out Observation Date and the Final Fixing Date: Share Basket and Reference Dates – Individual/Individual
- (x) Adjustment basis for Share Basket and Averaging Reference Dates: Not Applicable
- (xi) Trade Date: 7 October 2021
- (xii) Jurisdictional Event: Not Applicable
- (xiii) Jurisdictional Event Jurisdiction(s): Not Applicable
- (xiv) Share Substitution: Applicable
- (xv) Additional Disruption Events:
 - (a) Change in Law: Change in Law Option 1 Applicable
 - (b) Change of Exchange: Applicable
 - (c) Foreign Ownership Event: Not Applicable
 - (d) FX Disruption: Not Applicable
 - (e) Insolvency Filing: Applicable
 - (f) Hedging Disruption: Applicable
 - (g) Increased Cost of Hedging: Not Applicable
 - (h) Loss of Stock Borrow: Not Applicable
 - (i) Increased Cost of Stock Borrow: Not Applicable
- (xvi) Dividend Adjusted Performance: Not Applicable

In respect of the CRISPR Therapeutics Shares:

- (i) Share Issuer: CRISPR Therapeutics AG

- (ii) Share: The CRISPR Therapeutics Shares
- (iii) ISIN: CH0334081137
- (iv) Bloomberg Code: CRSP UQ <Equity>
- (v) Information Source: <https://www.nasdaq.com>
- (vi) Exchange: NASDAQ
- (vii) Related Exchange: All Exchanges
- (viii) Maximum Days of Disruption: Eight Scheduled Trading Days as specified in Asset Term 1
- (ix) Adjustment basis for Share Basket and Reference Dates: In respect of the Initial Setting Date, each Trigger Barrier Observation Date, the Knock-in Observation Date, the Knock-out Observation Date and the Final Fixing Date: Share Basket and Reference Dates – Individual/Individual
- (x) Adjustment basis for Share Basket and Averaging Reference Dates: Not Applicable
- (xi) Trade Date: 7 October 2021
- (xii) Jurisdictional Event: Not Applicable
- (xiii) Jurisdictional Event Jurisdiction(s): Not Applicable
- (xiv) Share Substitution: Applicable
- (xv) Additional Disruption Events:
 - (a) Change in Law: Change in Law Option 1 Applicable
 - (b) Change of Exchange: Applicable
 - (c) Foreign Ownership Event: Not Applicable
 - (d) FX Disruption: Not Applicable
 - (e) Insolvency Filing: Applicable
 - (f) Hedging Disruption: Applicable
 - (g) Increased Cost of Hedging: Not Applicable
 - (h) Loss of Stock Borrow: Not Applicable
 - (i) Increased Cost of Stock Borrow: Not Applicable

(xvi) Dividend Performance:	Adjusted	Not Applicable
56. Index-linked Securities:		Not Applicable
57. Commodity-linked Securities:		Not Applicable
58. Commodity Securities:	Index-linked	Not Applicable
59. ETF-linked Securities:		Not Applicable
60. ETC-linked Securities:		Not Applicable
61. FX-linked Securities:		Not Applicable
62. FX Index-linked Securities:		Not Applicable
63. Inflation Index-linked Securities:		Not Applicable
64. Interest Rate Securities:	Index-linked	Not Applicable
65. Cash Index-linked Securities:		Not Applicable
66. Multi-Asset Securities:	Basket-linked	Not Applicable
67. Valuation Time:		As determined in accordance with Equity-linked Securities Asset Term 1

GENERAL PROVISIONS

68. (i) Form of Securities:		Bearer Securities
(ii) Global Security:		Applicable
(iii) NGN Form:		Not Applicable
(iv) Intended to be held in a manner which would allow Eurosystem eligibility:		No. Whilst the designation is specified as "no" at the date of this Prospectus, should the Eurosystem eligibility criteria be amended in the future such that the Securities are capable of meeting them the Securities may then be deposited with one of the ICSDs as common safekeeper. Note that this does not necessarily mean that the Securities will then be recognised as eligible collateral for Eurosystem monetary policy and intra day credit operations by the Eurosystem at any time during their life. Such recognition will depend upon the European Central Bank being satisfied that Eurosystem eligibility criteria have been met
(v) The Issuer intends to permit indirect interests in the Securities to be held through CREST Depository Interests to be issued by the CREST Depository:		Not Applicable
69. Financial Centre(s):		Not Applicable

70. Business Centre(s): Not Applicable
71. Listing and Admission to Trading: Application has been made for the Securities to be listed on the Official List of the Luxembourg Stock Exchange and to be admitted to trading on the regulated market of the Luxembourg Stock Exchange with effect from, at the earliest, the Issue Date, provided, however, no assurance can be given that such application for listing and admission to trading will be granted (or, if granted, will be granted by the Issue Date or any specific date thereafter)
72. Security Codes and Ticker Symbols:
- ISIN: XS2387777555
- Common Code: 238777755
- Swiss Security Number: 112852847
- Telekurs Ticker: Not Applicable
- WKN Number: Not Applicable
73. Clearing and Trading:
- Clearing System(s) and any relevant identification number(s): Euroclear Bank S.A./N.V. and Clearstream Banking, *société anonyme*
74. Delivery: Delivery against payment
75. Agents:
- Calculation Agent: Credit Suisse International
One Cabot Square
London E14 4QJ
- Fiscal Agent: The Bank of New York Mellon, acting through its London Branch
One Canada Square
London E14 5AL
- Paying Agent(s): The Bank of New York Mellon, acting through its London Branch
One Canada Square
London E14 5AL
- Additional Agents: Not Applicable
76. Dealer(s): Credit Suisse International
77. Specified newspaper for the purposes of notices to Securityholders: Not Applicable
78. 871(m) Securities: The Issuer has determined that the Securities (without regard to any other transactions) should not be treated as transactions that are subject to U.S. withholding tax under section 871(m)
79. Prohibition of Sales to EEA Retail Investors: Applicable – see the cover page of this Securities Note

- Prohibition of Sales to UK Retail Investors: Applicable – see the cover page of this Securities Note
80. Additional U.S. Tax Selling Restrictions: Applicable – see "Additional U.S. Tax Selling Restrictions" under "United States", as set out in the section headed "Selling Restrictions" as incorporated by reference from the Original CS Trigger Redeemable and Phoenix Securities Note and as supplemented by the Supplement dated 3 August 2021 to the Original CS Trigger Redeemable and Phoenix Securities Note, each of which is incorporated by reference into this document
81. Additional Provisions: Not Applicable

PART B – OTHER INFORMATION

TERMS AND CONDITIONS OF THE OFFER

Not Applicable

INTERESTS OF NATURAL AND LEGAL PERSONS INVOLVED IN THE ISSUE

So far as the Issuer is aware, no person involved in the issue of the Securities has an interest material to the issue, save for any fees payable to the distributor(s).

The Securities will be sold by Credit Suisse Bank (Europe), S.A. (as an intermediary between the dealer and each distributor) ("**CSEB**") to the distributor(s) at a discount of up to 6 per cent. of the Issue Price per Security. Such discount represents the fee retained by the distributor(s) out of the Issue Price paid by investors, equivalent to approximately 2 per cent. per annum of the Specified Denomination per Security.

PERFORMANCE OF THE UNDERLYING ASSET(S) AND OTHER INFORMATION CONCERNING THE UNDERLYING ASSET(S)

Information about the past and future performance and volatility of the Underlying Assets can be found free of charge at: (a) in respect of each of the Arrowhead Pharmaceuticals Shares, the Ultragenyx Pharmaceutical Shares and the CRISPR Therapeutics Shares, <https://www.nasdaq.com> and (b) in respect of the Invitae Shares, <https://www.nyse.com> (but the information appearing on such website(s) does not form part of this Prospectus).


POST-ISSUANCE INFORMATION

The Issuer will not provide any post-issuance information with respect to the Underlying Assets, unless required to do so by applicable law or regulation.

REASONS FOR THE ISSUE, ESTIMATED NET PROCEEDS AND TOTAL EXPENSES


- | | |
|---------------------------------|--|
| (i) Reasons for the issue: | See "Use of Proceeds" section as incorporated by reference from the CS Trigger Redeemable and Phoenix Securities Note. |
| (ii) Estimated net proceeds: | USD 6,000,000. |
| (iii) Estimated total expenses: | Not Applicable. |

Signed on behalf of the Issuer:

By: 

Julien Bieren
Managing Director

Duly authorised

By: 
Duly authorised

Yogamoorthy Logan
Managing Director

GENERAL INFORMATION

- Approval and passporting for the purposes of the Prospectus Regulation:** This Summary and Securities Note accompanied by the Registration Document (which together constitute the Prospectus) has been approved by the *Commission de Surveillance du Secteur Financier* (the "CSSF"), as competent authority under the Prospectus Regulation. The CSSF only approves this Prospectus, consisting of this Summary and Securities Note and the Registration Document, as meeting the standards of completeness, comprehensibility and consistency imposed under Luxembourg and EU law pursuant to the Prospectus Regulation. By approving the Prospectus, the CSSF gives no undertaking as to the quality or economic and financial soundness of the Securities and quality or solvency of the Issuer in line with the provisions of the Law of 16 July 2019 implementing Regulation 2017/1129/EU of the European Parliament and of the Council on prospectuses for securities (the "**Luxembourg Prospectus Law**"). Such approval should not be considered as an endorsement of the Issuer or the quality of the Securities that are the subject of the Prospectus. Investors should make their own assessment as to the suitability of investing in the Securities.
- Responsibility Statement:** The Issuer accepts responsibility for the information contained in this Prospectus. To the best of the knowledge of the Issuer, the information contained in this document is in accordance with the facts and makes no omission likely to affect its import.
- No consent to use the Prospectus:** The Issuer does not consent to the use of the Prospectus by any person in connection with the making of an offer of the Securities to the public.
- Listing and admission to trading:** Application has been made for the Securities to be listed on the Official List of the Luxembourg Stock Exchange and to be admitted to trading on the regulated market of the Luxembourg Stock Exchange with effect from, at the earliest, the Issue Date. There can be no assurance that any such listing will be obtained, or if obtained, will be maintained. The regulated market of the Luxembourg Stock Exchange is a regulated market for the purposes of Directive 2014/65/EU on Markets in Financial Instruments (as amended, varied or replaced from time to time).
- Taxation:** The level and basis of taxation on the Securities and on the Securityholders and any reliefs from such taxation depend on the Securityholder's individual circumstances and could change at any time and may have an impact on the return received by the Securityholder.

The tax and regulatory characterisation of the Securities may change over the life of the Securities. Investors will therefore need to obtain advice from their own tax advisers to determine the specific tax consequences of the purchase, ownership, transfer and redemption, exercise or expiry or enforcement of the Securities.
- Consents and approvals:** The Issuer has obtained all necessary consents, approvals and authorisations in connection with the issue of the Securities. The issue of the Securities will be in accordance with the Organizational Guidelines and Regulations of Credit Suisse Group AG and the Issuer. No specific resolution of the Board of Directors of the Issuer is required.
- Public offer of Securities:** The Securities will be offered to any category of investors (including retail and wholesale), provided that such offer does not constitute an offer to the public of the Securities.
- Programme contractual documents available:** So long as any relevant Security remains outstanding, copies of the agency agreement and deeds of covenant of the Programme will be available for inspection free of charge during normal business hours on any business day (except Saturdays, Sundays and legal holidays) at the specified offices of the Paying Agent.
- Programme offering document available:** Copies of this Prospectus (including any supplement to this Prospectus, the Registration Document and any supplement to the Registration Document) and the CS Trigger Redeemable and Phoenix Securities Note (including any supplement to the CS Trigger Redeemable and Phoenix Securities Note) and the documents incorporated by reference in this Prospectus or the Registration Document are available:

- (a) in the case of this Prospectus, on the website of Credit Suisse (<https://derivative.credit-suisse.com>) by selecting "Final Terms and Securities Notes" under "Issuance Program / Base Prospectuses"; and
 - (b) in the case of the Registration Document and the CS Trigger Redeemable and Phoenix Securities Note, on the website of Credit Suisse (<https://derivative.credit-suisse.com>) by selecting "Trigger Redeemable and Phoenix Securities" under "Issuance Program / Base Prospectuses".
10. **Clearing:** The Securities will be accepted for clearance through the following clearing systems (which is the entity in charge of keeping the relevant records):
- (a) Euroclear Bank S.A./N.V. (1 Boulevard du Roi Albert II, B-1210 Brussels, Belgium); and
 - (b) Clearstream Banking, *société anonyme* (42 Avenue JF Kennedy, L-1855 Luxembourg).
11. **Information on websites:** Other than in relation to documents which are incorporated by reference herein (see "Documents Incorporated by Reference" in this Prospectus), no content of any website, cited or referred to in this Prospectus, shall be deemed to form part of, or be incorporated by reference into, this Prospectus, nor has any such content been scrutinised or approved by the CSSF.

REGISTERED OFFICE OF THE ISSUER

Credit Suisse AG

Paradeplatz 8
CH-8001
Zurich
Switzerland

PRINCIPAL PLACE BUSINESS OF THE LONDON BRANCH OF THE ISSUER

Credit Suisse AG, London Branch

One Cabot Square
London E14 4QJ
England

DEALER and CALCULATION AGENT

Credit Suisse International

One Cabot Square
London E14 4QJ
England

FISCAL AGENT and PAYING AGENT

The Bank of New York Mellon, acting through its London Branch

One Canada Square
London E14 5AL
England

LEGAL ADVISERS

as to English law

Ashurst LLP

London Fruit & Wool Exchange
1 Duval Square
London E1 6PW

AUDITORS

KPMG AG

Räffelstrasse 28
8045 Zurich
Switzerland

PricewaterhouseCoopers AG

Birchstrasse 160
CH-8050 Zurich
Switzerland

LUXEMBOURG LISTING AGENT

The Bank of New York Mellon SA/NV, Luxembourg Branch

Vertigo Building - Polaris
2-4 rue Eugène Ruppert
L-2453 Luxembourg